3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Sarcoma
4
Thyroid Cancer, Papillary
2
Salivary Gland Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Breast Neoplasms
2
Brain Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
39
Peripheral Blood Stem Cell Transplantation
32
fludarabine phosphate
30
Busulfan
26
Filgrastim
24
Cyclosporine
24
Mycophenolic Acid
22
Antilymphocyte Serum
22
Radiotherapy
20
Melphalan
16
Whole-Body Irradiation
15
Tacrolimus
14
Methylprednisolone
14
Methotrexate
13
Cord Blood Stem Cell Transplantation
12
Etoposide
10
sargramostim
5
Thiotepa
5
Temozolomide
5
Sirolimus
5
Rituximab
5
Bevacizumab
5
aldesleukin
4
Therapeutics
4
Granulocyte Colony-Stimulating Factor
4
Cytarabine
4
Carmustine
4
pembrolizumab
3
Vincristine
3
Topotecan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
entrectinib
×
Sarcoma
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA